BackInnate Pharma Overview

Innate Pharma Accounts Payable

Track Innate Pharma's accounts payable ($15M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$15.04M
89.77% YoYΔ $7.11M vs prior year quarter

Peer average

Loading

Innate Pharma Accounts Payable History

Loading

Innate Pharma vs. peers: Accounts Payable Comparison

Loading

Innate Pharma Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Innate Pharma (IPHA) FAQ

As of the most recent data (December 2025), IPHA shows a accounts payable of $15M. That compares with $7.9M in the prior-year period — up 89.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IPHA's accounts payable is now $15M (was $7.9M) — a 89.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Innate Pharma is outperforming or lagging.

Tracking IPHA's accounts payable over time shows whether Innate Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $15M That compares with $7.9M in the prior-year period — up 89.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Innate Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $15M) with ownership activity and broader fundamentals.

Innate Pharma's accounts payable is $15M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.